Home › Funds › Propel Bio Management, LLC › SABS
Propel Bio Management, LLC position in SABS
SAB Biotherapeutics Inc · Health Care
Propel Bio Management, LLC reported holding 1,187,422 shares of SABS (SAB Biotherapeutics Inc) in its Q3 2026 13F filing — a position valued at US$3.8M, representing 2.00% of its reported portfolio and ranking #17 among its reported holdings. Propel Bio Management, LLC has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's SABS position evolved
Propel Bio Management, LLC first disclosed a stake in SABS in Q4 2025 at 652,881 shares (US$2.4M). The position peaked in Q2 2026 at 1,076,578 shares, worth US$4.2M. Across 4 filings, Propel Bio Management, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,187,422 shares valued at US$3.8M — an increase of 110,844 shares quarter over quarter.. Notable position changes include a 55% increase in Q1 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 652.88K | $2.44M | New |
| Q1 2026 | 1.01M | $3.89M | Add |
| Q2 2026 | 1.08M | $4.20M | Add |
| Q3 2026 | 1.19M | $3.76M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB Biotherapeutics Inc) is a Health Care company. 71 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$21.9M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Vivo Capital, LLC 6.92M sh · $21.92M · Q3 2026
- Commodore Capital LP 2.87M sh · $11.19M · Q2 2026
- Spruce Street Capital LP 2.20M sh · $8.57M · Q2 2026
- Sessa Capital IM, L.P. 2.20M sh · $8.57M · Q2 2026
- Sanofi 2.20M sh · $6.97M · Q3 2026
- Seven Fleet Capital Management LP 736.08K sh · $2.87M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held SABS?
Propel Bio Management, LLC has disclosed SABS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Propel Bio Management, LLC's current position in SABS?
As of Q3 2026, Propel Bio Management, LLC holds 1.19M shares of SABS (SAB Biotherapeutics Inc), valued at $3.76M, representing 2.00% of its reported portfolio and ranking #17.
Has Propel Bio Management, LLC been buying or selling SABS?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in SABS. The position peaked in Q2 2026 at 1.08M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 71 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.